– Janssen’s state-of-the-art facility has potential to make profound and long-term contribution to global health and security, including pandemic preparedness efforts –
Leiden, The Netherlands – October 25, 2018 – Johnson & Johnson today unveiled a new, state-of-the-art vaccines launch facility that represents a significant investment by the company in novel vaccines development, global health and security, and pandemic preparedness efforts. The new facility in Leiden, the Netherlands has been built by Janssen Vaccines & Prevention B.V., part of the Janssen Pharmaceutical Companies of Johnson & Johnson. It features innovative technological and manufacturing platforms that can support the large-scale production of Janssen vaccines for late-stage (Phase 3) clinical trials and – pending regulatory approvals – the launch of new vaccines on a mass scale for global public use.
Janssen’s pipeline includes investigational vaccines to prevent some of the world’s deadliest infectious diseases, including HIV, Respiratory Syncytial Virus (RSV), influenza, Ebola and Zika. In addition to supporting the development and launch of these vaccines, the new facility can also support global pandemic preparedness efforts, including Janssen’s most recent collaboration with the Coalition for Epidemic Preparedness Innovations (CEPI) to develop a novel vaccine against Middle East Respiratory Syndrome (MERS).
Speaking at the official opening of the facility, His Excellency Bruno Bruins, Minister for Medical Care and Sport of The Netherlands said: “The Dutch health care system is one of the best in the world. The Netherlands has a long tradition of innovation, research and the creation of high-quality jobs. The decision of the European Medicines Agency (EMA) to relocate to Amsterdam has strengthened this position. The opening of this new Janssen Vaccines facility fits perfectly with our national heritage – and this development.”
The facility is the latest example of Janssen’s leadership in pharmaceutical research and development (R&D) in The Netherlands. It also helps to cement the company’s position as the biggest private investor in R&D across all industry sectors in the Benelux region.
“This new center represents a significant commitment by Johnson & Johnson in our mission to change the trajectory of human health,” said Johan Van Hoof, M.D., Global Therapeutic Area Head IDV, Vaccines, Janssen Pharmaceuticals R&D and Managing Director, Janssen Vaccines & Prevention B.V. “By investing locally, we hope to protect globally by ensuring that innovative and effective vaccines become available to the people that need them wherever they may live.”
A number of cutting-edge R&D platforms will be deployed at the vaccines launch facility, including Janssen’s proprietary AdVac® viral vector vaccines technology and the company’s PER.C6® manufacturing platform. The PER.C6® platform has the potential to enable high capacity, high speed and cost-effective manufacturing for multiple types of vaccines.
“We are very proud of this new facility, which represents years of planning, platform development and process optimization for novel vaccines,” said Dirk Redlich, Ph.D., Head Vaccine Process and Analytical Development, Janssen Research & Development, LLC. “The bottom line is that we constructed this state-of-the-art center because we have confidence in our ability to deliver transformational vaccines. Ultimately, this building represents our concrete belief that we can create a better world – for people today, and for generations to come.”
Operations within the facility are already underway, focused on producing clinical trial supplies for Janssen’s late-stage vaccine candidates, including for HIV. For more information on Janssen’s innovative work to develop new vaccines, please visit: www.Janssen.com
About the Janssen Pharmaceutical Companies of Johnson & Johnson
At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We bring together the best minds and pursue the most promising science. We are Janssen. We collaborate with the world for the health of everyone in it. Learn more at www.janssen.com. Follow us at @JanssenGlobal.
In The Netherlands, Janssen has 2,100 employees across sites in Breda, Leiden and Woerden. Our employees cover the full spectrum of pharmaceutical and vaccine activities including research & development (R&D), supply chain and market access. Follow us at @Janssen_Ned.
Janssen Vaccines & Prevention B.V. and Janssen Research & Development, LLC are part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
Cautions Concerning Forward-Looking Statements
This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding a new vaccines launch facility. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Vaccines & Prevention B.V., any of the other Janssen Pharmaceutical Companies and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: general industry conditions and competition; economic factors, such as interest rate and currency exchante rate fluctuations; challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action;] changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 31, 2017, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in the company’s most recently filed Quarterly Report on Form 10-Q, and the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Neither the Janssen Pharmaceutical Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.